Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Renneville et al. Blood Cancer Discovery 2021

ABSTRACT: Avadomide induces degradation of ZMYM2 fusion oncoproteins in hematologic malignancies

PROVIDER: PRJEB43161 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR5332024_1.fastq.gz	Fastqsanger.gz
	ERR5332024_2.fastq.gz	Fastqsanger.gz
	ERR5332015_1.fastq.gz	Fastqsanger.gz
	ERR5332015_2.fastq.gz	Fastqsanger.gz
	ERR5332018_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 6

Similar Datasets

Avadomide induces degradation of ZMYM2 fusion oncoproteins in hematologic malignancies

Project description:Renneville A, Gasser JA, Grinshpun DE , Jean Beltran PM, Udeshi ND, Dr. Mary E. Matyskiela , Clayton T, McConkey M, Viswanathan K, Tepper A, Guirguis AA, Sellar RS, Cotteret S, Marzac C, Saada V, de Botton S, Kiladjian J, Cayuela J, Rolfe M, Chamberlain PP, Carr SA, Ebert BL. 2021. Thalidomide analogs exert their therapeutic effects by binding to the CRL4CRBN E3 ubiquitin ligase, promoting ubiquitination and subsequent proteasomal degradation of specific protein substrates. Drug-induced degradation of IKZF1 and IKZF3 in B-cell malignancies demonstrates the clinical utility of targeting disease-relevant transcription factors for degradation. Here, we found that avadomide (CC-122) induces CRBN-dependent ubiquitination and proteasomal degradation of ZMYM2 (ZNF198), a transcription factor involved in balanced chromosomal rearrangements with FGFR1 and FLT3 in aggressive forms of hematologic malignancies. The minimal drug-responsive element of ZMYM2 is a zinc-chelating MYM domain and is contained in the N-terminal portion of ZMYM2 that is universally included in the derived fusion proteins. We demonstrate that avadomide has the ability to induce proteasomal degradation of ZMYM2-FGFR1 and ZMYM2-FLT3 chimeric oncoproteins, both in vitro and in vivo. Our findings suggest that patients with hematologic malignancies harboring these ZMYM2 fusion proteins may benefit from avadomide treatment.

2021-02-18 | MSV000086902 | MassIVE

Issues with reporting and interpretation of Khan et al. 2021.

Project description:A recent publication in BMC Infectious Diseases concerning the use of convalescent plasma for the treatment of COVID-19 had a number of major issues. This correspondence details specific instances of unclear reporting as well as major omissions when discussing the context of the trial. These render the study's findings and conclusions misleading.

| S-EPMC9215141 | biostudies-literature

Reply to Soman et al, Alffenaar et al, Metcalfe et al, and Raoult.

Project description: Not available

| S-EPMC4696596 | biostudies-literature

Cryobiopsy Compared with Surgical Lung Biopsy in ILD: Reply to Maldonado et al., Froidure et al., Bendstrup et al., Agarwal et al., Richeldi et al., Rajchgot et al., and Quadrelli et al.

Project description: Not available

| S-EPMC6812448 | biostudies-literature

Reply to Topeli et al. and to Akinosoglou et al.

Project description: Not available

| S-EPMC7328319 | biostudies-literature

Reply to Gueret et al. and to Hammond et al.

Project description: Not available